Latest News & Updates

Biologics Contribute to Growth in Pharma Products Cold-Chain Market

In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...

Wednesday, September 12, 2018 | Read More

FDA Researchers Explore Fundamental Chemical Reaction that Could Threaten the Quality of Therapeutic Protein Products

In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...

Tuesday, September 11, 2018 | Read More

Sentry representatives attend DCAT week

Sentry BioPharma Services is pleased to announce delegates from Sentry’s Business Development team will be in New York City attending the Drug, Chemical & Associated Technologies Association (DCAT) Week March 19th -22nd. The four-day conference brings together key sourcing, procurement and business...

Monday, March 19, 2018 | Read More

Controlled Substances

Controlled Substances: Advanced Security for Compliance and Confidence

Regulatory oversight shapes every dimension of controlled substances: licensing, registration, storage, security, use, inventory and controlled drug disposal. The DEA licenses Sentry to store, distribute, manage returns, recall and manage destruction of Schedule III-V controlled substances.  Sentry BioPharma Services provides the exacting care and management required to safeguard controlled substances which are brought into Sentry’s custody and care.  Sentry’s pharmaceutical import/export and drug product management expertise can address varying product and client needs, including packaging, distribution, storage, importation, exportation and destruction services for controlled drugs and materials.

Sentry’s culture of continuous improvement leads to consistent and reliable operations that support controlled substance product guardianship.  Redundant systems and extensive security measures assure clients that product safety, identity, strength, purity and quality (SISPQ) remain intact.  Sentry features which support this agenda include:

  • Auxiliary power feeds and back-up systems
  • Continuous (24/7) security monitoring
  • Foreign Trade Zone (FTZ) status which allows controlled substances to be internationally shipped directly to Sentry where DEA, Customs & Border Patrol (CBP) and FDA clearances can be obtained within the security provided by Sentry’s GMP facility
  • Physical plant security
  • Redundant HVAC systems
  • Secure data and document programs

For more information about how Sentry can meet safety and regulatory demands for packaging, storage, distribution and disposal of controlled drugs, contact Sentry via email or by phone at 1-866-757-7400.